Status:
COMPLETED
A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World
Lead Sponsor:
Pfizer
Conditions:
Leukemia, Myeloid, Acute
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this observational study is to describe treatment patterns and effectiveness outcomes in a sample of oncology patients treated for AML with Mylotarg through up to two additional relapsed/re...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of acute myeloid leukemia (AML) on or after 01 December 2014 through Clinical Research Nurse (CRN) review of provider documentation of AML diagnosis in the medical record;
- Receipt of Mylotarg at any point during first three lines of therapy following initial AML diagnosis;
- Age greater than or equal to 18 years at initial diagnosis of AML.
Exclusion
- \- Record of 1 or more of the following confounding diagnoses at any point before or after AML diagnosis: Acute lymphoblastic leukemia; acute promyelocytic leukemia, aggressive systemic mastocytosis; hypereosinophilic syndrome and/or chronic eosinophilic leukemia; dermatofibrosarcoma protuberans; gastrointestinal stromal tumors.
Key Trial Info
Start Date :
April 7 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2020
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT04337138
Start Date
April 7 2020
End Date
July 31 2020
Last Update
August 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
New York, New York, United States, 10017